← State of Embedded Finance 2026

AKASA

Can a purpose-built GenAI platform — trained on clinical and financial data at the health-system level — meaningfully reduce administrative costs and improve revenue integrity across the entire healthcare revenue cycle?

Founded2019
HQSouth San Francisco, California, USA
FoundersVarun Ganapathi, Co-founders unnamed in evidence
Total raised$205M
Latest roundSeries unknown, 2025 (Cleveland Clinic collaboration announced April 2025)
IndustryVertical SaaS / Healthcare
The story

Founded in 2019, AKASA began as an AI automation company for healthcare revenue cycle management (RCM), initially applying machine learning to tasks like claim status and prior authorization. As generative AI matured, AKASA pivoted to building custom large language models (LLMs) trained on each health system's clinical data, repositioning itself as the leading GenAI platform for the mid-revenue cycle — spanning coding, CDI, and clinical denials. The Cleveland Clinic partnership in 2025 cemented AKASA's position as a serious enterprise GenAI player in healthcare finance, with no embedded finance products of its own.

Last 12 months
2025-04
Product timeline
2019
AKASA founded to apply AI to healthcare revenue cycle management, targeting administrative inefficiencies.· pivot
2022
Achieved HITRUST Risk-based, 2-year Certification for its Unified Automation platform hosted on AWS.· banking
2023
Expanded GenAI platform solutions including Coding Optimizer and CDI Optimizer for mid-revenue cycle workflows.· pivot
2025
Announced strategic collaboration with Cleveland Clinic to deploy GenAI tools for healthcare coding and documentation across US locations.· acquisition
The stack
Accounting gap: none